What is the volume of distribution of eculizumab?

MEDICATION GUIDE. SOLIRIS® (so-leer-is). (eculizumab) injection, for intravenous use. What is the most important information I should know about SOLIRIS? Jan 1, 2022 ... Soliris® (eculizumab) is unproven and not medically necessary for treatment of Shiga toxin E. coli-related hemolytic uremic syndrome (STEC-HUS). Eculizumab is a humanized monoclonal antibody directed against C5 of the complement cascade and thereby inhibits the formation of C5a and C5b-9 membrane attack ... Oct 24, 2017 ... The US Food and Drug Administration (FDA) approved eculizumab as a treatment for adult patients with generalized myasthenia gravis (gMG) who are anti- ... The SOLIRIS Infusion Finder provides access to a locator tool, which shows sites providing infusion services. Jul 27, 2023 ... Soliris (eculizumab) has been approved in the European Union (EU) for expanded use to include the treatment of refractory generalised myasthenia ... SOLIRIS (eculizumab) is an FDA-approved prescription medicine used to treat adults with neuromyelitis optica spectrum disorder (NMOSD) Apr 1, 2024 ... SOLIRIS is a medicine that affects your immune system and may lower the ability of your immune system to fight infections. SOLIRIS increases ... May 28, 2024 ... The US Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare ... Mar 7, 2025 ... Soliris, whose active substance is eculizumab, is a first‐in‐class biologic therapy designed to inhibit a key protein in the complement cascade— ...